ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
3 announcements with these filters
Lupin Inc. licensed two oncology programs to Kaveri Therapeutics in exchange for an 82.2% stake, valued at ₹15.36 Crore.
Lupin's subsidiary Nanomi completed the acquisition of shares in MPPI. This increases Nanomi's effective shareholding in MPPI to 99.89%.
Lupin Limited incorporated a wholly owned subsidiary, Lupin (Thailand) Limited, on April 17, 2026. The new entity, based in Thailand, will focus on importing, marketing, and distributing pharmaceutical products. It has an initial paid-up capital of 3,000,000 Baht, entirely held by the parent company.